Journal of Isfahan Medical School

Journal of Isfahan Medical School

The Effects of Metformin Drug in Diabetic Patients Suffering from Concomitant Infection with Covid-19; A Review Study

Document Type : Review Article

Authors
Ayoub Shokoufamanesh 1
Hamid Nasri 2
Mohammadreza Khosravifarsani 3
1 MSc Epidemiology, Department of Public Health, Torbatjam Faculty of Medical Sciences, Torbat Jam, Iran
2 Professor, Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
3 Assistant Professor, Cancer Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran
10.48305/jims.v40.i702.1096
Abstract
Background: Diabetes is one of the most common co-morbidities and is associated with worse results in patients with coronavirus disease 2019 (COVID-19). The results showed that mortality was reduced among diabetics taking metformin compared with those not taking metformin. Therefore, the present study was conducted with the aim of providing reliable and up-to-date evidence about the effects of metformin drug in diabetic patients suffering from concomitant infection with COVID-19.
Methods: In this review, we searched PubMed, Embase, Cochrane and Google Scholar databases starting in December 2019 to find studies. We carried out a systematic search of English texts using the keywords "metformin" or "biguanides" and "coronavirus disease 2019" or "COVID-19". After reviewing the titles, summaries and complete texts, 28 studies were eventually included in the study.
Findings: The review found that most studies showed reduced mortality among metformin users compared to non-users among diabetics with COVID-19. In addition, the results indicate that metformin may inhibit viruses by increasing insulin susceptibility. However, some studies do not support the impact of metformin on
mortality reduction.
Conclusion: Results from this study show that metformin use in diabetic patients with COVID-19 is associated with decreased mortality. Of course, randomized controlled trials are necessary to confirm this outcome.
Keywords
Blood sugar
COVID-19
Diabetes mellitus
Metformin
Respiratory infection
Subjects
  1. Cheng X, Liu YM, Li H, Zhang X, Lei F, Qin JJ, et al. Metformin is associated with higher incidence of acidosis, but not mortality, in individuals with COVID-19 and pre-existing type 2 diabetes. Cell Metab 2020; 32(4): 537-47. e3.
  2. Hariyanto TI, Kurniawan A. Metformin use is associated with reduced mortality rate from coronavirus disease 2019 (COVID-19) infection. Obes Med 2020; 19: 100290.
  3. Crouse AB, Grimes T, Li P, Might M, Ovalle F, Shalev A. Metformin use is associated with reduced mortality in a diverse population with COVID-19 and diabetes. Front Endocrinol (Lausanne) 2021; 11: 600439.
  4. Scheen AJ. Metformin and COVID-19: from cellular mechanisms to reduced mortality. Diabetes Metab 2020; 46(6): 423-6.
  5. Peric S, Stulnig TM. Diabetes and COVID-19. Wien Klin Wochenschr 2020; 132(13): 356-61.
  6. Drucker DJ. Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications. Endocr Rev 2020; 41(3): bnaa011.
  7. Chen Y, Chen J, Gong X, Rong X, Ye D, Jin Y, et al. Clinical characteristics and outcomes of type 2 diabetes patients infected with COVID-19: a retrospective study. Engineering (Beijing) 2020; 6(10): 1170-7.
  8. Alkundi A, Mahmoud I, Musa A, Naveed S, Alshawwaf M. Clinical characteristics and outcomes of COVID-19 hospitalized patients with diabetes in the United Kingdom: a retrospective single centre study. Diabetes Res Clin Pract 2020; 165: 108263.
  9. American Diabetes Association. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes-2019. Diabetes Care 2019; 42(Suppl 1): S90-S102.
  10. Zhou F, Liu Y-M, Xie J, Li H, Lei F, Yang H, et al. Comparative impacts of ACE (angiotensin-converting enzyme) inhibitors versus angiotensin II receptor blockers on the risk of COVID-19 mortality. Hypertension 2020; 76(2): e15-e17.
  11. Esam Z. A proposed mechanism for the possible therapeutic potential of Metformin in COVID-19. Diabetes Res Clin Pract 2020; 167: 108282.
  12. EL‐Arabey AA, Abdalla M. Metformin and COVID-19: A novel deal of an old drug. J Med Virol 2020; 92(11): 2293.
  13. Samuel SM, Varghese E, Büsselberg D. Therapeutic potential of metformin in COVID-19: reasoning for its protective role. Trends Microbiol 2021; 29(10): 894-907.
  14. Bramante CT, Ingraham NE, Murray TA, Marmor S, Hovertsen S, Gronski J, et al. Observational Study of Metformin and Risk of Mortality in Persons Hospitalized with COVID-19. medRxiv 2020.
  15. Luo P, Qiu L, Liu Y, Liu Xl, Zheng Jl, Xue HY, et al. Metformin treatment was associated with decreased mortality in COVID-19 patients with diabetes in a retrospective analysis. Am J Trop Med Hyg 2020; 103(1): 69-72.
  16. Mrozikiewicz-Rakowska B, Bałut D, Bąk PM, Kleibert M, Zieliński J. The Phenomenon of metformin in COVID-19 Pandemic among polish patients with type 2 diabetes mellitus. Am Heart J
    2021; 242: 173.
  17. Ursini F, Ciaffi J, Landini MP, Meliconi R. COVID-19 and diabetes: Is metformin a friend or foe? Diabetes Res Clin Pract 2020; 164: 108167.
  18. Chen Y, Yang D, Cheng B, Chen J, Peng A, Yang C, et al. Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication. Diabetes Care 2020; 43(7): 1399-407.
  19. Bałut D, Kleibert M, Bąk PM, Zieliński J, Mrozikiewicz-Rakowska B. The influence of metformin on the rate of COVID-19 vaccination among diabetes type 2 patients in Poland. Metabolism 2022; 128: 155031.
  20. Dziubak A, Wójcicka G, Wojtak A, Bełtowski J. Metabolic effects of metformin in the failing heart. Int J Mol Sci 2018; 19(10): 2869.
  21. Li Y, Yang X, Yan P, Sun T, Zeng Z, Li S. Metformin in patients with COVID-19: a systematic review and meta-analysis. Front Med (Lausanne) 2021; 8: 704666.
  22. Maideen NMP, Jumale A, Balasubramaniam R. Drug interactions of metformin involving drug transporter proteins. Adv Pharm Bull 2017; 7(4): 501-5.
  23. Calabrese AT, Coley KC, DaPos SV, Swanson D, Rao RH. Evaluation of prescribing practices: risk of lactic acidosis with metformin therapy. Arch Intern Med 2002; 162(4): 434-7.
  24. Scott KA, Martin JH, Inder WJ. Acidosis in the hospital setting: is metformin a common precipitant? Intern Med J 2010; 40(5): 342-6.
Journal of Isfahan Medical School
Volume 40, Issue 702
2nd Week, March
March and April 2023
Pages 1096-1102

  • Receive Date 26 November 2022
  • Revise Date 18 March 2023
  • Accept Date 13 February 2023